Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jul 9:12:1759720X20939410.
doi: 10.1177/1759720X20939410. eCollection 2020.

IBD considerations in spondyloarthritis

Affiliations
Review

IBD considerations in spondyloarthritis

Caroline Di Jiang et al. Ther Adv Musculoskelet Dis. .

Abstract

Spondyloarthritis (SpA) may be regarded a family of auto-inflammatory conditions with inflammation focused on the joints. These form part of a wider family of immune-mediated inflammatory diseases, which include inflammatory bowel diseases (IBD). These conditions share common elements of pathophysiology and it is perhaps unsurprising, therefore, that individuals with SpA frequently manifest gastrointestinal inflammation, to which the physician managing the patient with SpA must be alert. In this article, we review the shared epidemiology and pathophysiology of these conditions, before discussing approaches to diagnosis and management of inflammatory gastrointestinal pathology in patients seen in rheumatology clinics. In particular, we discuss the difference between non-specific gastrointestinal inflammation commonly described in this patient group and the more specific diagnosis of Crohn's disease or ulcerative colitis. We describe the appropriate diagnostic workup for patients suspected of having IBD. In addition, we discuss how a diagnosis of IBD can inform treatment selection, highlighting important differences in treatment choice, drug dosing, monitoring and drug safety for this particular comorbid patient population.

Keywords: crohn’s disease; inflammatory bowel disease; spondyloarthritis; ulcerative colitis.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: TR has received research/educational grants and/or speaker/consultation fees from Abbvie, BMS, Celgene, Ferring, Gilead, GSK, LabGenius, Janssen, Mylan, MSD, Novartis, Pfizer, Sandoz, Takeda and UCB. CDJ: none relevant.

References

    1. Fragoulis GE, Liava C, Daoussis D, et al. Inflammatory bowel diseases and spondyloarthropathies: from pathogenesis to treatment. World J Gastroenterol 2019; 25: 2162–2176. - PMC - PubMed
    1. Proft F, Poddubnyy D. Ankylosing spondylitis and axial spondyloarthritis: recent insights and impact of new classification criteria. Ther Adv Musculoskelet Dis 2018; 10: 129–139. - PMC - PubMed
    1. National Institute for Health and Care Excellence (UK). Spondyloarthritis in over 16s: diagnosis and management, https://www.nice.org.uk/guidance/ng65 (2017; 22 April 2020). - PubMed
    1. Harbord M, Annese V, Vavricka SR, et al.; European Crohn’s and Colitis Organisation. The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. J Crohns Colitis 2016; 10: 239–254. - PMC - PubMed
    1. Kopylov U, Starr M, Watts C, et al. Detection of Crohn disease in patients with spondyloarthropathy: the SpACE capsule study. J Rheumatol 2018; 45: 498–505. - PubMed

LinkOut - more resources